Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY

ALNYLAM PHARMACEUTICALS, INC. (ALNY)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/16/2018 02/20/2018 02/21/2018 02/22/2018 02/23/2018 Date
122.88(c) 120.83(c) 119.18(c) 119.86(c) 121.42 Last
653 512 396 096 559 425 417 141 392 843 Volume
+0.94% -1.67% -1.37% +0.57% +1.30% Change
More quotes
Financials ($)
Sales 2018 132 M
EBIT 2018 -665 M
Net income 2018 -677 M
Finance 2018 670 M
Yield 2018 -
Sales 2019 383 M
EBIT 2019 -514 M
Net income 2019 -512 M
Finance 2019 610 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 84,0x
EV / Sales2019 29,0x
Capitalization 11 719 M
More Financials
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics.It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined... 
More about the company
Surperformance© ratings of Alnylam Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on ALNYLAM PHARMACEUTICALS, I
02/15Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial R..
AQ
02/15ALNYLAM PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
AQ
02/08ALNYLAM PHARMACEUTICALS : Study Results from Alnylam Pharmaceuticals, Inc. in th..
AQ
02/08ALNYLAM PHARMACEUTICALS : Announces FDA Acceptance of New Drug Application NDA a..
AQ
02/08ALNYLAM PHARMACEUTICALS (NASDAQ : ALNY) reported earnings of ($1.48) per share m..
AQ
02/08ALNYLAM PHARMACEUTICALS, INC. (NASDA : ALNY) Files An 8-K Results of Operations ..
AQ
02/08ALNYLAM PHARMACEUTICALS : reports 4Q loss
AQ
02/08ALNYLAM PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, F..
AQ
02/08ALNYLAM PHARMACEUTICALS : Reports Fourth Quarter and Full Year 2017 Financial Re..
BU
02/08ALNYLAM PHARMACEUTICALS, INC. : Alnylam Pharmaceuticals, Inc to Host Earnings Ca..
AC
More news
Sector news : Biotechnology & Medical Research - NEC
12:30pSANOFI : Says U.S. Waiting Period for Bioverativ Has Expired
DJ
02/22SANGAMO THERAPEUTICS : Surges on Therapy Collaboration Deal with Kite -- Market ..
DJ
02/22Sangamo in $3 billion gene-editing deal with Gilead
RE
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
05:57pUp and Down the Ladder: Job Changes.. the latest comings and goings.. recogni.. 
04:34pPeer Review - Seeking greater gender diversity, Alnylam promotes four female ..
4
02/202,700 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Acquired by Daiwa Securit.. 
02/20$ALNY - Alnylam Pharmaceuticals #ALNY Given Coverage Optimism Rating of 0.16 .. 
02/16Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by First Trust Advisors LP  
More tweets
Qtime:57
News from SeekingAlpha
08:00a3 THINGS IN BIOTECH YOU SHOULD LEARN : February 22, 2018 
02/202018 Brings New Challenges And Opportunities For Alnylam Pharmaceuticals 
02/13Alnylam Pharmaceuticals (ALNY) Presents At BIO CEO & Investor Conference - Sl.. 
02/12Biotech Forum Daily Digest For February 12th 
02/09Key events next week - healthcare 
Chart ALNYLAM PHARMACEUTICALS, I
Duration : Period :
Alnylam Pharmaceuticals, I Technical Analysis Chart | ALNY | US02043Q1076 | 4-Traders
Technical analysis trends ALNYLAM PHARMACEUTICALS, I
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 154 $
Spread / Average Target 29%
EPS Revisions
Managers
NameTitle
John M. Maraganore Chief Executive Officer & Director
Barry E. Greene President
Michael W. Bonney Chairman
Yvonne L. Greenstreet Chief Operating Officer & Executive Vice President
Manmeet Singh Soni Chief Financial Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ALNYLAM PHARMACEUTICALS, INC.-6.19%11 719
CELLTRION, INC.--.--%34 966
IQVIA HOLDINGS INC1.90%20 749
LONZA GROUP-6.95%19 587
INCYTE CORPORATION-10.56%17 877
NEKTAR THERAPEUTICS44.76%13 613